CNS Pharmaceuticals (NASDAQ: CNSP) is a biopharmaceutical company focused on developing innovative therapies for central nervous system disorders, specifically aggressive brain cancers. The company today announced its confidence in sharing the results from an interim analysis on one of its lead treatment candidates, Berubicin, with the public before the end of the year. Berubicin is … Continue reading InvestorNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) to Release Interim Data by Year End for Lead Treatment Candidate Berubicin